Trial Profile

A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies (KEYNOTE-A04)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 1206 (Primary) ; BI 1206 (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions
Acronyms KEYNOTE-A04
Sponsors BioInvent International

08 Jan 2025 According to BioInvent International media release, the company is looking forward to further data from the study next year.
03 Jan 2025 Planned number of patients changed from 90 to 197.
03 Jan 2025 Planned End Date changed from 1 Jan 2026 to 1 Nov 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com